What changed
What changedIn the first nine months of 2026, Novartis reported a net income of $7.6 billion on total sales of $42.0 billion. In October, the company also announced approvals for the drugs Rhapsido, Pluvicto, and Fabhalta.

Company history
October 2026
NOVARTIS AG: 12 recorded developments from 3 official sources in 2026-10.
- 2026-10-27: Novartis acquired Myricx Bio, adding antibody-drug conjugates targeting B7-H3 and HER2 to its oncology pipeline. Source
- 2026-10-27: In the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange. Source
- 2026-10-27: As of Q3 2026, the company has a long-term credit rating of Aa3 with Moody’s Ratings and AA- with S&P Global Ratings. Source
- 2026-10-27: Japan’s MHLW approved Fabhalta for the treatment of IgA nephropathy, and the FDA granted traditional approval for the same indication. Source
- 2026-10-27: Novartis is scheduled to hold a 'Meet Novartis Management 2026' event in London, UK. Source
- 2026-10-27: US sales were USD 6.4 billion, European sales were USD 4.3 billion, and sales in emerging growth markets were USD 3.8 billion. Source
- 2026-10-27: The company acquired Excellergy, Inc. for USD 0.9 billion and Pikavation Therapeutics, Inc. for USD 1.8 billion using the optional concentration test. Source
- 2026-10-27: Net cash outflows used in financing activities in the current-year period amounted to USD 0.9 billion. Source
- 2026-10-27: Novartis met the primary endpoint in the Phase III REMODEL-1/-2 studies for remibrutinib in relapsing multiple sclerosis. Source
- 2026-10-27: Novartis discontinued the remibrutinib project for myasthenia gravis following a futility analysis readout. Source
- 2026-10-27: Novartis has a global temporary pause on the YTB323 programs for active refractory lupus nephritis, active refractory systemic lupus erythematosus, systemic sclerosis, myositis, and ANCA associated vasculitis. Source
- 2026-10-28: Units to be sold: 6000; aggregate market value: 933180 USD; units outstanding: 1908151679 Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Novartis raised full-year 2026 core operating income guidance to expected growth in the low single-digits from a previous expectation of low single-digit decline, while net sales guidance remains unchanged at low single-digit growth.
Said October 27, 2026 · Period named: Full-year 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 2,927,793 | $417,415,428 | -3.9% | Q3 2026 |
| Fidelity (FMR) | 2,029,130 | $289,292,898 | -1.4% | Q3 2026 |
| Citadel Advisors | 1,613,666 | $230,060,362 | +403.0% | Q3 2026 |
| Renaissance Technologies | 661,631 | $94,328,732 | -16.0% | Q3 2026 |
| Millennium Management | 503,168 | $71,736,662 | -33.6% | Q3 2026 |
| State Street | 50,378 | $7,256,495 | -0.6% | Q3 2026 |
| Two Sigma Investments | 28,461 | $4,057,685 | +103.4% | Q3 2026 |
| D. E. Shaw & Co. | 17,772 | $2,533,754 | — | Q3 2026 |
| Wellington Management | 11,045 | $1,730,972 | — | Q2 2026 |
| T. Rowe Price | 63,394 | $9,039 | +80.9% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.